INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3401, 'Lidocaine', 'Lemborexant', 'Moderate', 'Coadministration with lemborexant may decrease the plasma concentrations and pharmacologic effects of CYP450 2B6 substrates. The proposed mechanism is lemborexant-mediated induction of the CYP450 2B6 isoenzyme.', 'DDInter', 'Caution is advised if lemborexant is used concomitantly with drugs that are substrates of CYP450 2B6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lemborexant is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if lemborexant is used concomitantly with drugs that are substrates of CYP450 2B6.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3401/', '', 'Procaine, Tetracaine, Tetracaine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Quinidine, Propafenone, More', 'Suvorexant, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Ramelteon, Eszopiclone, Methohexital, Ethchlorvynol, Tasimelteon, Melatonin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3402, 'Lindane', 'Lidocaine', 'Moderate', 'Lindane penetrates human skin and has the potential to cause central nervous system toxicity. Seizures have been reported after excessive use or oral ingestion of lindane. There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline).', 'DDInter', 'Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Lindane should be used according to recommended dosage and directions for application.', 'Synergism', 'Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3402/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, More', 'Disulfiram', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3403, 'Lonafarnib', 'Lidocaine', 'Moderate', 'Coadministration with lonafarnib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Lonafarnib is a potent CYP450 3A time-dependent and mechanism-based inhibitor in vitro.', 'DDInter', 'Caution is advised when lonafarnib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lonafarnib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects. The prescribing information recommends avoiding concomitant use of lonafarnib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges when possible. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.', 'Metabolism', 'Caution is advised when lonafarnib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3403/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3404, 'Lorazepam', 'Lidocaine', 'Moderate', 'The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.', 'DDInter', 'Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.', 'Synergism', 'Caution is advised during concurrent use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3404/', '', 'Pheniramine, Flurbiprofen, Povidone-iodine, Tocainide, Dronedarone, Procainamide, Bretylium, Moricizine, Ibutilide, Zinc sulfate, Zinc acetate, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3405, 'Lorlatinib', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3405/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Promethazine, Neomycin, Chlorhexidine, More', 'Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3406, 'Lusutrombopag', 'Lidocaine', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of lusutrombopag, which is a substrate of both efflux transporter proteins.', 'DDInter', 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors. Pharmacologic response to lusutrombopag should be monitored more closely following initiation, discontinuation, or change of dosage of the concomitant P-gp or BCRP inhibitor.', 'Distribution', 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3406/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3407, 'Mefloquine', 'Lidocaine', 'Moderate', 'Mefloquine is a myocardial depressant and can cause ECG abnormalities. Theoretically, coadministration with other agents that can affect cardiac conduction (e.g., antiarrhythmic agents, beta blockers, calcium channel blockers, certain antihistamines, tricyclic antidepressants, phenothiazines, some neuroleptics) may result in additive effects and increased risk of ventricular arrhythmias including ventricular tachycardia and torsade de pointes.', 'DDInter', 'Caution and clinical monitoring are recommended if mefloquine is used in combination with other drugs that can prolong the QT interval or otherwise affect cardiac conduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes or other arrhythmia such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution and clinical monitoring are recommended if mefloquine is used in combination with other drugs that can prolong the QT interval or otherwise affect cardiac conduction.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3407/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, More', 'Artesunate, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Halofantrine, Proguanil, Sulfadoxine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3408, 'Mephenytoin', 'Lidocaine', 'Minor', 'Hydantoins may increase the hepatic metabolism of intravenous lidocaine. Serum lidocaine levels may be decreased, and increased dosage may be necessary. Caution is recommended, however, since the possible myocardial-depressant effects of both drugs may be additive. Hemodynamic and electrocardiographic status should be monitored during therapy. No action is required unless an interaction is suspected.', 'DDInter', '-', 'Metabolism, Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3408/', '', 'Procaine, Tetracaine, Tetracaine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Amiodarone, More', 'Brivaracetam, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Phensuximide, Ganaxolone, Phenacemide, Trimethadione, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3409, 'Methylphenobarbital', 'Lidocaine', 'Minor', 'Coadministration with barbiturates may decrease the plasma concentrations of lidocaine. The proposed mechanism is induction of lidocaine metabolism via CYP450 3A4. These changes were not statistically significant. Because lidocaine is not available commercially for oral administration, the interaction may be of limited clinical relevance.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3409/', '', 'Procaine, Tetracaine, Tetracaine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Amiodarone, More', 'Brivaracetam, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Phensuximide, Ganaxolone, Phenacemide, Trimethadione, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3410, 'Metocurine', 'Lidocaine', 'Moderate', 'Lidocaine may enhance the effect of neuromuscular blocking agents. The mechanism is not known, but may include inhibition of acetylcholine release from presynaptic neurons.', 'DDInter', 'Patients should be closely monitored for increased and/or prolonged neuromuscular blockade and apnea during and after concomitant therapy.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3410/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Povidone-iodine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3411, 'Metoprolol', 'Lidocaine', 'Moderate', 'Some beta-blockers may increase lidocaine levels and risk of toxicity. The proposed mechanism is enzyme inhibition and/or decreased cardiac output and hepatic blood flow resulting in decreased hepatic metabolism of lidocaine. In addition beta-blockers and lidocaine may also have additive negative inotropic effects on the heart.', 'DDInter', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension. Lidocaine levels should be obtained when clinically necessary. If toxicity is suspected, the lidocaine infusion should be decreased, as possible.', 'Metabolism, Synergism', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3411/', '', 'Ivabradine', 'Procaine, Tetracaine, Tripelennamine, Clemastine, Tetracaine, Pheniramine, Povidone-iodine, Bacitracin, Bretylium, Moricizine, Ibutilide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3412, 'Mexiletine', 'Lidocaine', 'Moderate', 'Mexiletine may increase the serum lidocaine levels and toxicity. The mechanism is unknown.', 'DDInter', 'Management consists of monitoring the patient for symptoms of neurotoxicity, monitoring plasma levels and decreasing the lidocaine dosage if an interaction is suspected.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3412/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Moricizine, Lidocaine, Flecainide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3413, 'Midazolam', 'Lidocaine', 'Moderate', 'The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.', 'DDInter', 'Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.', 'Synergism', 'Caution is advised during concurrent use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3413/', '', 'Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Neomycin, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, More', 'Suvorexant, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Ramelteon, Eszopiclone, Methohexital, Ethchlorvynol, Tasimelteon, Melatonin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3414, 'Mifepristone', 'Lidocaine', 'Moderate', 'Based on in vitro inhibition data, coadministration with mifepristone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by mifepristone.', 'DDInter', 'Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever mifepristone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3414/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Neomycin, Chlorhexidine, Povidone-iodine, More', 'Ulipristal, Danazol, Ospemifene, Bazedoxifene, Prasterone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3415, 'Mitotane', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3415/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3416, 'Mivacurium', 'Lidocaine', 'Moderate', 'Lidocaine may enhance the effect of neuromuscular blocking agents. The mechanism is not known, but may include inhibition of acetylcholine release from presynaptic neurons.', 'DDInter', 'Patients should be closely monitored for increased and/or prolonged neuromuscular blockade and apnea during and after concomitant therapy.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3416/', '', 'Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Povidone-iodine, Flurbiprofen, More', 'Botulinum toxin type A', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3417, 'Modafinil', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3417/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Neomycin, Flurbiprofen, Povidone-iodine, More', 'Amphetamine, Pemoline, Atomoxetine, Lisdexamfetamine, Solriamfetol, Caffeine, Dexmethylphenidate, Dextroamphetamine, Citicoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3418, 'Morphine (liposomal)', 'Lidocaine', 'Moderate', 'INTERVAL: Concomitant epidural administration of local anesthetics may affect the release of morphine sulfate from the liposomal formulation. The mechanism of interaction is unknown. The use of liposomal morphine with anesthetics other than lidocaine with epinephrine (test dose) and bupivacaine (analgesic dose) has not been evaluated. In vitro studies suggest a similar interaction with other amide local anesthetics. No data are available for ester-type local anesthetics.', 'DDInter', 'To minimize the potential for interaction between liposomal morphine and lidocaine-epinephrine test dose (1.5%-1:200,000, 3 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 15 minutes after the test dose before administering the morphine. Following administration of an analgesic dose of bupivacaine (0.25%, 20 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 30 minutes before administering the morphine. Liposomal morphine should not be mixed with any other medications. Once it has been administered, no other medication should be administered into the epidural space for at least 48 hours.', 'Others', 'To minimize the potential for interaction between liposomal morphine and lidocaine-epinephrine test dose (1.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3418/', '', 'Procaine, Tetracaine, Tripelennamine, Tetracaine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, More', 'Opium, Eluxadoline, Diphenoxylate, Difenoxin, Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Opium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3419, 'Nadolol', 'Lidocaine', 'Moderate', 'Some beta-blockers may increase lidocaine levels and risk of toxicity. The proposed mechanism is enzyme inhibition and/or decreased cardiac output and hepatic blood flow resulting in decreased hepatic metabolism of lidocaine. In addition beta-blockers and lidocaine may also have additive negative inotropic effects on the heart.', 'DDInter', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension. Lidocaine levels should be obtained when clinically necessary. If toxicity is suspected, the lidocaine infusion should be decreased, as possible.', 'Metabolism, Synergism', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3419/', '', 'Procaine, Tetracaine, Tripelennamine, Clemastine, Tetracaine, Pheniramine, Chlorhexidine, Povidone-iodine, Bacitracin, Propafenone, Procainamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3420, 'Nafcillin', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3420/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Sulbactam, Oxacillin, Dicloxacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Cloxacillin, Benzylpenicillin, Ampicillin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3421, 'Nebivolol', 'Lidocaine', 'Moderate', 'Some beta-blockers may increase lidocaine levels and risk of toxicity. The proposed mechanism is enzyme inhibition and/or decreased cardiac output and hepatic blood flow resulting in decreased hepatic metabolism of lidocaine. In addition beta-blockers and lidocaine may also have additive negative inotropic effects on the heart.', 'DDInter', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension. Lidocaine levels should be obtained when clinically necessary. If toxicity is suspected, the lidocaine infusion should be decreased, as possible.', 'Metabolism, Synergism', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3421/', '', 'Procaine, Tetracaine, Tripelennamine, Clemastine, Tetracaine, Pheniramine, Neomycin, Chlorhexidine, Povidone-iodine, Bacitracin, Tocainide, More', 'Ivabradine, Olmesartan, Azilsartan medoxomil, Candesartan, Eprosartan, Sacubitril, Aliskiren', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3422, 'Nefazodone', 'Lidocaine', 'Moderate', 'Coadministration with nefazodone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by nefazodone.', 'DDInter', 'Caution is advised if nefazodone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. A lower initial dosage, as well as clinical and laboratory monitoring, may be appropriate for some drugs.', 'Metabolism', 'Caution is advised if nefazodone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3422/', '', 'Procaine, Tetracaine, Tetracaine, Pheniramine, Neomycin, Flurbiprofen, Povidone-iodine, Bacitracin, Tocainide, Procainamide, Flecainide, More', 'Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Isocarboxazid, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3423, 'Nelfinavir', 'Lidocaine', 'Moderate', 'Coadministration with nelfinavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by nelfinavir.', 'DDInter', 'Caution is advised if nelfinavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nelfinavir is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if nelfinavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3423/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3424, 'Neomycin', 'Lidocaine', 'Minor', 'Limited in vitro data suggest that some aminoglycosides may enhance the neuromuscular blocking properties of lidocaine. Data are available for neomycin only. No special precautions are necessary.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3424/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Flurbiprofen, More', 'Rifamycin, Miconazole, Polymyxin B, Fidaxomicin, Rifaximin, Paromomycin, Lidocaine, Povidone-iodine, Bacitracin, Rifamycin, Oxytetracycline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3425, 'Netilmicin', 'Lidocaine', 'Minor', 'Limited in vitro data suggest that some aminoglycosides may enhance the neuromuscular blocking properties of lidocaine. Data are available for neomycin only. No special precautions are necessary.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3425/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Chlorhexidine, More', 'Ganciclovir, Norfloxacin, Rifamycin, Oxytetracycline, Polymyxin B, Lomefloxacin, Trifluridine, Benzylpenicillin, Ampicillin, Levofloxacin, Povidone-iodine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3426, 'Nevirapine', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3426/', '', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Bacitracin, Flurbiprofen, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3427, 'Nitazoxanide', 'Lidocaine', 'Moderate', 'Coadministration with nitazoxanide may increase the free plasma concentrations of drugs and/or their active metabolites that are highly bound to plasma proteins. The pharmacologic effects of some drugs may be increased by this interaction. The proposed mechanism is competitive displacement from protein binding sites by tizoxanide, the active metabolite of nitazoxanide that is greater than 99.9% bound to plasma proteins.', 'DDInter', 'Caution is advised when other highly protein-bound drugs are used with nitazoxanide, particularly those with a narrow therapeutic index. Patients should be monitored more closely following the addition or withdrawal of nitazoxanide. When performing therapeutic drug monitoring, total plasma concentrations should be interpreted cautiously due to the possibility of increased free (unbound) drug.', 'Distribution', 'Caution is advised when other highly protein-bound drugs are used with nitazoxanide, particularly those with a narrow therapeutic index.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3427/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Tinidazole, Quinacrine, Secnidazole, Atovaquone, Furazolidone, Trimetrexate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3428, 'Obeticholic acid', 'Lidocaine', 'Moderate', 'Coadministration with obeticholic acid may increase the plasma concentrations of drugs that are substrates of the CYP450 1A2 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 1A2 activity by obeticholic acid and its glycine and taurine conjugates.', 'DDInter', 'Caution is advised when obeticholic acid is prescribed with drugs that undergo metabolism by CYP450 1A2, particularly those with a narrow therapeutic range such as theophylline or tizanidine. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever obeticholic acid is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when obeticholic acid is prescribed with drugs that undergo metabolism by CYP450 1A2, particularly those with a narrow therapeutic range such as theophylline or tizanidine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3428/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Cholic Acid, Odevixibat, Maralixibat, Chenodeoxycholic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3429, 'Octreotide', 'Lidocaine', 'Moderate', 'Somatostatin analogs (e.g., octreotide, lanreotide) can decrease heart rate and may potentiate the bradycardic effects of drugs like beta-blockers, calcium channel blockers, digitalis glycosides, and certain antiarrhythmic agents (e.g., class I antiarrhythmics, adenosine, amiodarone).', 'DDInter', 'Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers. Heart rate and blood pressure should be monitored.', 'Synergism', 'Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3429/', '', 'Norethisterone, Nafarelin, Cetrorelix, Ganirelix, Relugolix, Gonadorelin', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Bacitracin, Flurbiprofen, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3430, 'Olaparib', 'Lidocaine', 'Moderate', 'Coadministration with olaparib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 1A2 and/or 2B6. The proposed mechanism, based on in vitro data, is increased clearance due to olaparib-mediated induction of CYP450 1A2 and/or 2B6.', 'DDInter', 'Caution is advised if olaparib is used concomitantly with drugs that are substrates of CYP450 1A2 and/or 2B6. Pharmacologic response and serum levels should be monitored more closely whenever olaparib is added to or withdrawn from therapy with these drugs. Dosage adjustments may be required if an interaction is suspected.', 'Metabolism', 'Caution is advised if olaparib is used concomitantly with drugs that are substrates of CYP450 1A2 and/or 2B6.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3430/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3431, 'Omeprazole', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3431/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Flurbiprofen, Povidone-iodine, Bacitracin, More', 'Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Esomeprazole, Vonoprazan, Levofloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3432, 'Osilodrostat', 'Lidocaine', 'Moderate', 'Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2 and/or 2C19. Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2 and a mild to borderline moderate inhibitor of CYP450 2C19.', 'DDInter', 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2 and/or 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2 and/or 2C19, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3432/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, More', 'Ketoconazole', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3433, 'Osimertinib', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3433/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, More', 'Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3434, 'Oxazepam', 'Lidocaine', 'Moderate', 'The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.', 'DDInter', 'Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.', 'Synergism', 'Caution is advised during concurrent use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3434/', '', 'Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Neomycin, Propafenone, Dronedarone, Tocainide, Procainamide, Disopyramide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3435, 'Oxcarbazepine', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3435/', '', 'Procaine, Tetracaine, Tetracaine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Neomycin, Propafenone, Tocainide, Procainamide, More', 'Brivaracetam, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Phensuximide, Ganaxolone, Phenacemide, Trimethadione, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3436, 'Pancuronium', 'Lidocaine', 'Moderate', 'Lidocaine may enhance the effect of neuromuscular blocking agents. The mechanism is not known, but may include inhibition of acetylcholine release from presynaptic neurons.', 'DDInter', 'Patients should be closely monitored for increased and/or prolonged neuromuscular blockade and apnea during and after concomitant therapy.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3436/', '', 'Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Povidone-iodine, Flurbiprofen, More', 'Botulinum toxin type A', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3437, 'Pasireotide', 'Lidocaine', 'Moderate', 'The risk of significant bradycardia and atrioventricular (AV) block may be increased during concomitant treatment of pasireotide with other drugs that slow heart rate or AV conduction such as beta-blockers, calcium channel blockers, atazanavir, digitalis, flecainide, lacosamide, mefloquine, moricizine, and propafenone.', 'DDInter', 'Pasireotide has not been studied in patients receiving other bradycardic drugs. Because bradycardia and AV block are recognized risk factors for torsade de pointes arrhythmia, electrocardiographic monitoring is recommended prior to initiation of pasireotide and during treatment. Dose adjustments of beta blockers and calcium channel blockers or correction of electrolyte disturbances may be necessary.', 'Synergism', 'Pasireotide has not been studied in patients receiving other bradycardic drugs.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3437/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, More', 'Norethisterone, Nafarelin, Cetrorelix, Ganirelix, Relugolix, Gonadorelin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3438, 'Penbutolol', 'Lidocaine', 'Moderate', 'Some beta-blockers may increase lidocaine levels and risk of toxicity. The proposed mechanism is enzyme inhibition and/or decreased cardiac output and hepatic blood flow resulting in decreased hepatic metabolism of lidocaine. In addition beta-blockers and lidocaine may also have additive negative inotropic effects on the heart.', 'DDInter', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension. Lidocaine levels should be obtained when clinically necessary. If toxicity is suspected, the lidocaine infusion should be decreased, as possible.', 'Metabolism, Synergism', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3438/', '', 'Procaine, Tetracaine, Tripelennamine, Clemastine, Tetracaine, Pheniramine, Neomycin, Chlorhexidine, Povidone-iodine, Bacitracin, Procainamide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3439, 'Pentobarbital', 'Lidocaine', 'Minor', 'Coadministration with barbiturates may decrease the plasma concentrations of lidocaine. The proposed mechanism is induction of lidocaine metabolism via CYP450 3A4. These changes were not statistically significant. Because lidocaine is not available commercially for oral administration, the interaction may be of limited clinical relevance.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3439/', '', 'Procaine, Tetracaine, Tetracaine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Amiodarone, More', 'Suvorexant, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Ramelteon, Eszopiclone, Methohexital, Ethchlorvynol, Tasimelteon, Melatonin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3440, 'Pexidartinib', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3440/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Neomycin, More', 'Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3441, 'Phenobarbital', 'Lidocaine', 'Minor', 'Coadministration with barbiturates may decrease the plasma concentrations of lidocaine. The proposed mechanism is induction of lidocaine metabolism via CYP450 3A4. These changes were not statistically significant. Because lidocaine is not available commercially for oral administration, the interaction may be of limited clinical relevance.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3441/', '', 'Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Tocainide, Procainamide, Flecainide, Mexiletine, Bretylium, More', 'Suvorexant, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Ramelteon, Eszopiclone, Methohexital, Ethchlorvynol, Tasimelteon, Melatonin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3442, 'Phenylbutazone', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3442/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Neomycin, More', 'Fenoprofen, Meclofenamic acid, Glucosamine, Oxaprozin, Chondroitin sulfate, Esomeprazole, Tolmetin, Sulindac, Mefenamic acid, Tolmetin, Tolazoline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3443, 'Phenytoin', 'Lidocaine', 'Minor', 'Hydantoins may increase the hepatic metabolism of intravenous lidocaine. Serum lidocaine levels may be decreased, and increased dosage may be necessary. Caution is recommended, however, since the possible myocardial-depressant effects of both drugs may be additive. Hemodynamic and electrocardiographic status should be monitored during therapy. No action is required unless an interaction is suspected.', 'DDInter', '-', 'Metabolism, Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3443/', '', 'Brivaracetam, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Phensuximide, Ganaxolone, Phenacemide, Trimethadione, More', 'Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Neomycin, Propafenone, Tocainide, Procainamide, Flecainide, Bretylium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3444, 'Pindolol', 'Lidocaine', 'Moderate', 'Some beta-blockers may increase lidocaine levels and risk of toxicity. The proposed mechanism is enzyme inhibition and/or decreased cardiac output and hepatic blood flow resulting in decreased hepatic metabolism of lidocaine. In addition beta-blockers and lidocaine may also have additive negative inotropic effects on the heart.', 'DDInter', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension. Lidocaine levels should be obtained when clinically necessary. If toxicity is suspected, the lidocaine infusion should be decreased, as possible.', 'Metabolism, Synergism', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3444/', '', 'Procaine, Tetracaine, Tripelennamine, Clemastine, Tetracaine, Pheniramine, Neomycin, Chlorhexidine, Povidone-iodine, Bacitracin, Propafenone, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3445, 'Pipecuronium', 'Lidocaine', 'Moderate', 'Lidocaine may enhance the effect of neuromuscular blocking agents. The mechanism is not known, but may include inhibition of acetylcholine release from presynaptic neurons.', 'DDInter', 'Patients should be closely monitored for increased and/or prolonged neuromuscular blockade and apnea during and after concomitant therapy.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3445/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Povidone-iodine, More', 'Botulinum toxin type A', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3446, 'Plazomicin', 'Lidocaine', 'Minor', 'Limited in vitro data suggest that some aminoglycosides may enhance the neuromuscular blocking properties of lidocaine. Data are available for neomycin only. No special precautions are necessary.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3446/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Chlorhexidine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3447, 'Polyethylene glycol (3350 with electrolytes)', 'Lidocaine', 'Moderate', 'The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.', 'DDInter', 'Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.', 'Antagonism', 'Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3447/', '', 'Procaine, Tetracaine, Tetracaine, Pheniramine, Neomycin, Chlorhexidine, Povidone-iodine, Bacitracin, Tocainide, Moricizine, Bretylium, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3448, 'Posaconazole', 'Lidocaine', 'Moderate', 'Coadministration with posaconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by posaconazole.', 'DDInter', 'Caution is advised if posaconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever posaconazole is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if posaconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3448/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, More', 'Micafungin, Caspofungin, Miconazole, Oteseconazole, Ketoconazole, Flucytosine, Anidulafungin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3449, 'Prilocaine', 'Lidocaine', 'Major', 'Prilocaine can cause dose-related methemoglobin formation via its ortho-toluidine metabolite. Coadministration with other oxidizing agents that can also induce methemoglobinemia including other local anesthetics (e.g., benzocaine, lidocaine), antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Prilocaine should be used with caution in the presence of other methemoglobin-inducing drugs. Patients should be closely monitored to ensure adequate perfusion and oxygenation during treatment with prilocaine. Methemoglobin levels should be monitored and oxygen administered whenever possible. Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.', 'Synergism', 'Prilocaine should be used with caution in the presence of other methemoglobin-inducing drugs.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3449/', '', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Lidocaine, Chloroprocaine, Levobupivacaine, Tetracaine, Mepivacaine, Procaine, Articaine, Etidocaine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3450, 'Primidone', 'Lidocaine', 'Minor', 'Coadministration with barbiturates may decrease the plasma concentrations of lidocaine. The proposed mechanism is induction of lidocaine metabolism via CYP450 3A4. These changes were not statistically significant. Because lidocaine is not available commercially for oral administration, the interaction may be of limited clinical relevance.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3450/', '', 'Procaine, Tetracaine, Tetracaine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Neomycin, Tocainide, Procainamide, Flecainide, More', 'Suvorexant, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Ramelteon, Eszopiclone, Methohexital, Ethchlorvynol, Tasimelteon, Melatonin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3451, 'Procainamide', 'Lidocaine', 'Moderate', 'Limited data suggest that the combination of lidocaine and procainamide may result in an increased risk of conduction abnormalities, including complete AV heart block, and increased risk of nervous system side effects such as restlessness and hallucinations. Patients with preexisting conduction abnormalities are at higher risk for conduction abnormalities with the combination.', 'DDInter', 'Close monitoring of the patient''s hemodynamics, ECG, and mental status is recommended, especially in high-risk patients.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3451/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Moricizine, Lidocaine, Flecainide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3452, 'Propafenone', 'Lidocaine', 'Minor', 'Propafenone minimally inhibits the hepatic metabolism of lidocaine. Increased plasma concentrations of lidocaine may entail worse nervous system side effects of longer duration. Also, the negative effects these drugs may have on myocardial contractility may be additive. The patient should be monitored for nervous system side effects such as dysgeusia, paresthesias, and light-headedness. During coadministration, hemodynamic status should be monitored and lidocaine dosage should be reduced as necessary.', 'DDInter', '-', 'Metabolism, Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3452/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, More', 'Moricizine, Lidocaine, Flecainide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3453, 'Proparacaine (ophthalmic)', 'Lidocaine', 'Moderate', 'Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).', 'DDInter', 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.', 'Synergism', 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3453/', '', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3454, 'Propranolol', 'Lidocaine', 'Moderate', 'Some beta-blockers may increase lidocaine levels and risk of toxicity. The proposed mechanism is enzyme inhibition and/or decreased cardiac output and hepatic blood flow resulting in decreased hepatic metabolism of lidocaine. In addition beta-blockers and lidocaine may also have additive negative inotropic effects on the heart.', 'DDInter', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension. Lidocaine levels should be obtained when clinically necessary. If toxicity is suspected, the lidocaine infusion should be decreased, as possible.', 'Metabolism, Synergism', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3454/', '', 'Procaine, Tetracaine, Tripelennamine, Clemastine, Tetracaine, Pheniramine, Chlorhexidine, Povidone-iodine, Bacitracin, Dofetilide, Bretylium, More', 'Ivabradine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3455, 'Quazepam', 'Lidocaine', 'Moderate', 'The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.', 'DDInter', 'Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.', 'Synergism', 'Caution is advised during concurrent use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3455/', '', 'Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, Povidone-iodine, Neomycin, Quinidine, Propafenone, Dronedarone, Tocainide, Procainamide, More', 'Suvorexant, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Ramelteon, Eszopiclone, Methohexital, Ethchlorvynol, Tasimelteon, Melatonin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3456, 'Raloxifene', 'Lidocaine', 'Minor', 'Raloxifene is more than 95% protein bound. Caution should be exercised if raloxifene is coadministered with other highly protein-bound drugs. The mechanism is displacement of the drug from its protein-binding site by raloxifene. Displacement may lead to increased free plasma concentrations and potentiate toxicity of drugs affected by raloxifene. Formal in-vitro studies indicate that raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. The clinician may want to use caution when raloxifene is used with other highly-protein bound drugs, such as diazepam, diazoxide, or lidocaine.', 'DDInter', '-', 'Distribution', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3456/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, More', 'Ulipristal, Danazol, Ospemifene, Bazedoxifene, Prasterone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3457, 'Rapacuronium', 'Lidocaine', 'Moderate', 'Lidocaine may enhance the effect of neuromuscular blocking agents. The mechanism is not known, but may include inhibition of acetylcholine release from presynaptic neurons.', 'DDInter', 'Patients should be closely monitored for increased and/or prolonged neuromuscular blockade and apnea during and after concomitant therapy.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3457/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Povidone-iodine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3458, 'Remimazolam', 'Lidocaine', 'Moderate', 'The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.', 'DDInter', 'Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.', 'Synergism', 'Caution is advised during concurrent use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3458/', '', 'Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Quinidine, Propafenone, Dronedarone, Tocainide, Procainamide, More', 'Suvorexant, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Ramelteon, Eszopiclone, Methohexital, Ethchlorvynol, Tasimelteon, Melatonin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3459, 'Rifabutin', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3459/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Tinidazole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3460, 'Rifampicin', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3460/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, More', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Pretomanid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3461, 'Rifapentine', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3461/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Neomycin, More', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Pretomanid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3462, 'Rilonacept', 'Lidocaine', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3462/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3463, 'Ritonavir', 'Lidocaine', 'Moderate', 'Coadministration with ritonavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by ritonavir.', 'DDInter', 'Caution is advised if ritonavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ritonavir is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if ritonavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3463/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Neomycin, Chlorhexidine, Povidone-iodine, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3464, 'Rocuronium', 'Lidocaine', 'Moderate', 'Lidocaine may enhance the effect of neuromuscular blocking agents. The mechanism is not known, but may include inhibition of acetylcholine release from presynaptic neurons.', 'DDInter', 'Patients should be closely monitored for increased and/or prolonged neuromuscular blockade and apnea during and after concomitant therapy.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3464/', '', 'Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Povidone-iodine, Flurbiprofen, More', 'Botulinum toxin type A', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3465, 'Ropivacaine', 'Lidocaine', 'Moderate', 'The effect of ropivacaine may be additive when used concomitantly with other amide type local anesthetics.', 'DDInter', 'Use caution if these drugs are coadministered.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3465/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Lidocaine, Chloroprocaine, Levobupivacaine, Tetracaine, Mepivacaine, Procaine, Articaine, Etidocaine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3466, 'Rucaparib', 'Lidocaine', 'Moderate', 'Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2. The proposed mechanism is decreased clearance due to rucaparib-mediated inhibition of CYP450 1A2.', 'DDInter', 'Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3466/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Neomycin, Chlorhexidine, Povidone-iodine, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3467, 'Rufinamide', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3467/', '', 'Procaine, Tetracaine, Tetracaine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Propafenone, Tocainide, More', 'Brivaracetam, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Phensuximide, Ganaxolone, Phenacemide, Trimethadione, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3468, 'Saquinavir', 'Lidocaine', 'Major', 'Coadministration with saquinavir may significantly increase the plasma concentrations of some antiarrhythmic agents such as amiodarone, bepridil, flecainide, lidocaine, propafenone, and quinidine. The mechanism is decreased clearance due to inhibition of CYP450 3A4- and 2D6-mediated metabolism by saquinavir, particularly when coadministered with ritonavir as a pharmacokinetic booster. Although clinical data are lacking, the interaction could conceivably lead to serious and/or life-threatening reactions including QT interval prolongation and ventricular arrhythmias such as ventricular tachycardia and torsade de pointes.', 'DDInter', 'The use of saquinavir-ritonavir in combination with amiodarone, bepridil, flecainide, lidocaine, propafenone, and quinidine is considered contraindicated.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3468/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3469, 'Sarilumab', 'Lidocaine', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3469/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3470, 'Satralizumab', 'Lidocaine', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3470/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3471, 'Secobarbital', 'Lidocaine', 'Minor', 'Coadministration with barbiturates may decrease the plasma concentrations of lidocaine. The proposed mechanism is induction of lidocaine metabolism via CYP450 3A4. These changes were not statistically significant. Because lidocaine is not available commercially for oral administration, the interaction may be of limited clinical relevance.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3471/', '', 'Procaine, Tetracaine, Tetracaine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Amiodarone, Tocainide, More', 'Suvorexant, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Ramelteon, Eszopiclone, Methohexital, Ethchlorvynol, Tasimelteon, Melatonin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3472, 'Secukinumab', 'Lidocaine', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3472/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3473, 'Selpercatinib', 'Lidocaine', 'Moderate', 'Coadministration with selpercatinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by selpercatinib. The interaction may be particularly important for sensitive substrates or those that demonstrate a narrow therapeutic index.', 'DDInter', 'Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever selpercatinib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3473/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, More', 'Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3474, 'Siltuximab', 'Lidocaine', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3474/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3475, 'Sirolimus', 'Lidocaine', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', 'DDInter', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3475/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Chlorhexidine, Povidone-iodine, More', 'Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Nandrolone, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3476, 'Nitrous acid', 'Lidocaine', 'Major', 'Sodium nitrite can cause methemoglobin formation, which diminishes oxygen-carrying capacity of the blood. Coadministration with other agents that are also associated with methemoglobinemia including local anesthetics (e.g., benzocaine, lidocaine, prilocaine), antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide (primarily in infants), nitrofurantoin (primarily in infants), phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.', 'DDInter', 'Sodium nitrite should be used with caution in the presence of other methemoglobin-inducing drugs. Patients should be closely monitored to ensure adequate perfusion and oxygenation during treatment with sodium nitrite. Methemoglobin levels should be monitored and oxygen administered whenever possible.', 'Synergism', 'Sodium nitrite should be used with caution in the presence of other methemoglobin-inducing drugs.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3476/', '', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, Methionine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3477, 'Somapacitan', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3477/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3478, 'Somatrem', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3478/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3479, 'Somatotropin', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3479/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3480, 'Sotalol', 'Lidocaine', 'Moderate', 'Some beta-blockers may increase lidocaine levels and risk of toxicity. The proposed mechanism is enzyme inhibition and/or decreased cardiac output and hepatic blood flow resulting in decreased hepatic metabolism of lidocaine. In addition beta-blockers and lidocaine may also have additive negative inotropic effects on the heart.', 'DDInter', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension. Lidocaine levels should be obtained when clinically necessary. If toxicity is suspected, the lidocaine infusion should be decreased, as possible.', 'Metabolism, Synergism', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3480/', '', 'Procaine, Tetracaine, Tripelennamine, Clemastine, Tetracaine, Pheniramine, Neomycin, Povidone-iodine, Bacitracin, Bretylium, Moricizine, More', 'Ivabradine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3481, 'St. John''s Wort', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3481/', '', 'Procaine, Tetracaine, Tetracaine, Pheniramine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Quinidine, More', 'Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Isocarboxazid, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3482, 'Stiripentol', 'Lidocaine', 'Moderate', 'The concomitant administration of stiripentol may significantly increase plasma concentrations, pharmacologic effects, and toxicities of drugs that are substrates of CYP450 2C19, 3A4, and/or 2D6. The mechanism is inhibition of cytochrome P-450 metabolism by stiripentol.', 'DDInter', 'Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use. Dosage adjustments may be required if increased plasma levels or effects are observed.', 'Metabolism', 'Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3482/', '', 'Procaine, Tetracaine, Tetracaine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, Povidone-iodine, Neomycin, Tocainide, Procainamide, More', 'Brivaracetam, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Perampanel, Fenfluramine, Phensuximide, Ganaxolone, Phenacemide, Trimethadione, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3483, 'Streptomycin', 'Lidocaine', 'Minor', 'Limited in vitro data suggest that some aminoglycosides may enhance the neuromuscular blocking properties of lidocaine. Data are available for neomycin only. No special precautions are necessary.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3483/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Chlorhexidine, More', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, Ethionamide, Pretomanid, Rifamycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3484, 'Succinylcholine', 'Lidocaine', 'Moderate', 'Lidocaine may enhance the effect of neuromuscular blocking agents. The mechanism is not known, but may include inhibition of acetylcholine release from presynaptic neurons.', 'DDInter', 'Patients should be closely monitored for increased and/or prolonged neuromuscular blockade and apnea during and after concomitant therapy.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3484/', '', 'Botulinum toxin type A', 'Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3485, 'Sulfinpyrazone', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3485/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Neomycin, More', 'Lesinurad, Febuxostat, Pegloticase, Colchicine, Probenecid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3486, 'Tacrolimus', 'Lidocaine', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', 'DDInter', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3486/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Povidone-iodine, Tocainide, Moricizine, More', 'Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3487, 'Tazemetostat', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3487/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Neomycin, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3488, 'Telaprevir', 'Lidocaine', 'Moderate', 'Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, may increase the plasma concentrations of certain antiarrhythmic agents including flecainide, lidocaine, and propafenone. The mechanism of interaction has not been described. The interaction has not been specifically studied, but could conceivably lead to serious and/or life-threatening reactions including cardiac arrhythmias and other toxicities if levels are significantly increased.', 'DDInter', 'Caution is advised if boceprevir or telaprevir must be used with flecainide, lidocaine, or propafenone. Pharmacologic response and plasma antiarrhythmic drug levels should be monitored more closely whenever the HCV NS3/4A protease inhibitor is added to or withdrawn from therapy, and the antiarrhythmic dosage adjusted as necessary.', 'Others', 'Caution is advised if boceprevir or telaprevir must be used with flecainide, lidocaine, or propafenone.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3488/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3489, 'Telithromycin', 'Lidocaine', 'Moderate', 'Coadministration with telithromycin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by telithromycin.', 'DDInter', 'Caution is advised if telithromycin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever telithromycin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if telithromycin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3489/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, More', 'Troleandomycin, Dirithromycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3490, 'Temazepam', 'Lidocaine', 'Moderate', 'The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.', 'DDInter', 'Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.', 'Synergism', 'Caution is advised during concurrent use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3490/', '', 'Suvorexant, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Ramelteon, Eszopiclone, Methohexital, Ethchlorvynol, Tasimelteon, Melatonin, More', 'Pheniramine, Neomycin, Flurbiprofen, Povidone-iodine, Bacitracin, Propafenone, Dronedarone, Tocainide, Procainamide, Disopyramide, Mexiletine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3491, 'Temsirolimus', 'Lidocaine', 'Moderate', 'Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the macrolide immunosuppressant and/or the coadministered drug(s). The mechanism is decreased drug clearance due to competitive inhibition of CYP450 3A4 activity.', 'DDInter', 'Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever a macrolide immunosuppressant or another substrate of CYP450 3A4 is added to or withdrawn from therapy, and the dosage(s) adjusted as necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3491/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Chlorhexidine, More', 'Entrectinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Fedratinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3492, 'Teriflunomide', 'Lidocaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of lidocaine, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3492/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Neomycin, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3493, 'Tetracaine (ophthalmic)', 'Lidocaine', 'Moderate', 'Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).', 'DDInter', 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.', 'Synergism', 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3493/', '', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3494, 'Tetracaine (topical)', 'Lidocaine', 'Moderate', 'Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).', 'DDInter', 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.', 'Synergism', 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3494/', '', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', 'Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3495, 'Thallous Chloride', 'Lidocaine', 'Moderate', 'Coadministration of certain drugs may alter the myocardial uptake of thallous chloride Tl-201 and interfere with results of myocardial imaging studies. Drugs that increase or decrease coronary blood flow or potassium uptake may alter the biodistribution of thallous chloride Tl-201.', 'DDInter', 'Clinicians should be aware of possible diagnostic interference by these drugs.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3495/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3496, 'Tilmanocept', 'Lidocaine', 'Moderate', 'Locally injected anesthetics have been reported to reduce lymphatic flow of Technetium Tc 99m tilmanocept in animal studies.', 'DDInter', 'Co-injection (mixture) of local anesthetics with Technetium Tc 99m tilmanocept is not recommended due to potential impairment of lymph nodal mapping.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3496/', '', 'Clemastine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, Flurbiprofen, Ibuprofen, Chlorhexidine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3497, 'Timolol', 'Lidocaine', 'Moderate', 'Some beta-blockers may increase lidocaine levels and risk of toxicity. The proposed mechanism is enzyme inhibition and/or decreased cardiac output and hepatic blood flow resulting in decreased hepatic metabolism of lidocaine. In addition beta-blockers and lidocaine may also have additive negative inotropic effects on the heart.', 'DDInter', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension. Lidocaine levels should be obtained when clinically necessary. If toxicity is suspected, the lidocaine infusion should be decreased, as possible.', 'Metabolism, Synergism', 'Patients receiving concurrent therapy should be monitored for drowsiness, mental status changes, bradycardia, and hypotension.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3497/', '', 'Procaine, Tetracaine, Tripelennamine, Clemastine, Tetracaine, Pheniramine, Neomycin, Chlorhexidine, Povidone-iodine, Bacitracin, Procainamide, More', 'Apraclonidine, Methazolamide, Neostigmine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Brinzolamide, Guanethidine, Levobunolol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3498, 'Tobramycin', 'Lidocaine', 'Minor', 'Limited in vitro data suggest that some aminoglycosides may enhance the neuromuscular blocking properties of lidocaine. Data are available for neomycin only. No special precautions are necessary.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3498/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Chlorhexidine, Povidone-iodine, More', 'Ganciclovir, Norfloxacin, Rifamycin, Oxytetracycline, Polymyxin B, Lomefloxacin, Trifluridine, Benzylpenicillin, Ampicillin, Levofloxacin, Povidone-iodine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3499, 'Tocainide', 'Lidocaine', 'Moderate', 'INTERVAL: Lidocaine and tocainide are structurally similar, and each crosses the blood-brain barrier. Their central nervous system side effects, such as agitation, disorientation, and seizures may be additive.', 'DDInter', 'Management consists of cautiously starting patients on tocainide six hours before stopping lidocaine infusions, then starting the next maintenance dose of tocainide six hours after the lidocaine drip has ended. The patient''s heart rhythm and clinical response should be monitored during this time.', 'Synergism', 'Management consists of cautiously starting patients on tocainide six hours before stopping lidocaine infusions, then starting the next maintenance dose of tocainide six hours after the lidocaine drip has ended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3499/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Moricizine, Lidocaine, Flecainide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (3500, 'Tocilizumab', 'Lidocaine', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/3500/', '', 'Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Promethazine, Bacitracin, More', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More', 1767369485);
